Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL9603824 | 0.92 | C3AR1 (0.39) | NOD1CTSSGLP1RC3AR1SIRT1 | |
| SCHEMBL30481170 | 0.89 | NOD1 (0.43) | NOD1GLP1RSIRT6SIRT1SLC6A5 | |
| SCHEMBL30481161 | 0.89 | NOD1 (0.43) | NOD1GLP1RSIRT6SIRT1SLC6A5 | |
| SCHEMBL12292041 | 0.85 | C3AR1 (0.41) | NOD1C3AR1SIRT1NPY4R | |
| SCHEMBL30892327 | 0.83 | NOD1 (0.55) | NOD1NPY4R | |
| SCHEMBL8209135 | 0.83 | TGM2 (0.39) | CTSSC3AR1CTSLNPY4R | |
| SCHEMBL29875551 | 0.83 | C3AR1 (0.40) | NOD1C3AR1SIRT6SIRT1SLC6A5 | |
| SCHEMBL19975767 | 0.82 | SIRT6 (0.48) | NOD1GLP1RC3AR1SIRT6SIRT1 | |
| SCHEMBL14089438 | 0.81 | NPY4R (0.42) | NOD1GLP1RC3AR1NPY4R | |
| SCHEMBL30471509 | 0.81 | NOD1 (0.46) | NOD1SIRT6SIRT1SLC6A5NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | NOD1 3377/4885CTSS 3139/4885CTSK 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.